| |
| |
|
| Insider
Information: |
Curran Terrie |
| Relationship: |
Director |
| City: |
New York |
| State: |
NY |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
4 |
|
| Direct
Shares |
419,471 |
|
|
Indirect Shares
|
3,840 |
|
|
| Direct
Value |
$79,225 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
423,311 |
|
|
| Total
Value |
$79,225 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Celgene Corp |
CELG |
|
2019-11-20 |
0 |
2019-11-20 |
0 |
Premium* |
|
|
Phathom Pharmaceuticals, Inc. |
PHAT |
|
2024-03-22 |
410,784 |
2024-03-22 |
3,840 |
Premium* |
|
|
Myovant Sciences Ltd. |
MYOV |
Director |
2023-03-10 |
0 |
2021-09-01 |
0 |
Premium* |
|
|
Arcutis Biotherapeutics, Inc. |
ARQT |
Director |
2023-05-31 |
8,687 |
2022-06-01 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
42 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 2
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| CELG |
Celgene Corp |
PRES., GLBL INFLAM. AND IMMUN. |
• – – |
2019-11-20 |
4 |
A |
$0.00 |
$0 |
D/D |
32,868 |
37,181 |
0 |
- |
|
| PHAT |
Phathom Pharmaceuticals, ... |
President and Chief Executive |
• • – |
2022-01-19 |
4 |
A |
$0.00 |
$0 |
D/D |
41,250 |
44,095 |
0 |
- |
|
| PHAT |
Phathom Pharmaceuticals, ... |
President and Chief Executive |
• • – |
2022-05-19 |
4 |
A |
$0.00 |
$0 |
D/D |
12,000 |
76,595 |
0 |
- |
|
| ARQT |
Arcutis Biotherapeutics, ... |
Director |
– • – |
2022-06-01 |
4 |
A |
$0.00 |
$0 |
D/D |
4,312 |
4,312 |
0 |
- |
|
| PHAT |
Phathom Pharmaceuticals, ... |
President and Chief Executive |
• • – |
2022-09-01 |
4 |
A |
$0.00 |
$0 |
D/D |
7,500 |
85,246 |
0 |
- |
|
| PHAT |
Phathom Pharmaceuticals, ... |
President and Chief Executive |
• • – |
2023-01-19 |
4 |
A |
$0.00 |
$0 |
D/D |
97,500 |
182,628 |
0 |
- |
|
| ARQT |
Arcutis Biotherapeutics, ... |
Director |
– • – |
2023-05-31 |
4 |
A |
$0.00 |
$0 |
D/D |
4,375 |
8,687 |
0 |
- |
|
| PHAT |
Phathom Pharmaceuticals, ... |
President and Chief Executive |
• • – |
2023-07-14 |
4 |
A |
$0.00 |
$0 |
D/D |
200,000 |
389,671 |
0 |
- |
|
| CELG |
Celgene Corp |
See remarks |
• – – |
2017-09-25 |
4 |
AS |
$143.89 |
$248,498 |
D/D |
(1,727) |
3,925 |
0 |
- |
|
| PHAT |
Phathom Pharmaceuticals, ... |
President and Chief Executive |
• • – |
2021-03-22 |
4 |
AS |
$43.24 |
$498,751 |
D/D |
(11,513) |
0 |
0 |
- |
|
| MYOV |
Myovant Sciences Ltd. |
Director |
– • – |
2021-09-01 |
4 |
AS |
$25.00 |
$284,325 |
D/D |
(11,373) |
0 |
0 |
% |
|
| MYOV |
Myovant Sciences Ltd. |
Director |
– • – |
2021-09-02 |
4 |
AS |
$25.03 |
$929,489 |
D/D |
(37,135) |
0 |
0 |
% |
|
| MYOV |
Myovant Sciences Ltd. |
Director |
– • – |
2021-09-09 |
4 |
AS |
$25.58 |
$124,063 |
D/D |
(4,850) |
0 |
0 |
% |
|
| PHAT |
Phathom Pharmaceuticals, ... |
President and Chief Executive |
• • – |
2023-03-01 |
4 |
AS |
$8.54 |
$12,265 |
D/D |
(1,436) |
175,371 |
0 |
- |
|
| PHAT |
Phathom Pharmaceuticals, ... |
President and Chief Executive |
• • – |
2022-05-13 |
4 |
B |
$7.41 |
$151,835 |
D/D |
20,500 |
64,595 |
2.81 |
- |
|
| PHAT |
Phathom Pharmaceuticals, ... |
President and Chief Executive |
• • – |
2023-04-06 |
4 |
B |
$7.82 |
$101,025 |
D/D |
12,919 |
188,290 |
2.81 |
- |
|
| CELG |
Celgene Corp |
See remarks |
• – – |
2017-08-01 |
4 |
D |
$135.18 |
$75,430 |
D/D |
(558) |
5,652 |
0 |
- |
|
| CELG |
Celgene Corp |
See remarks |
• – – |
2017-12-19 |
4 |
D |
$107.06 |
$73,122 |
D/D |
(683) |
5,007 |
0 |
- |
|
| CELG |
Celgene Corp |
SEE REMARKS |
– – – |
2018-05-04 |
4 |
D |
$86.89 |
$74,378 |
D/D |
(856) |
6,651 |
0 |
- |
|
| CELG |
Celgene Corp |
SEE REMARKS |
• – – |
2018-12-16 |
4 |
D |
$68.20 |
$83,954 |
D/D |
(1,231) |
7,920 |
0 |
- |
|
| CELG |
Celgene Corp |
SEE REMARKS |
• – – |
2019-05-02 |
4 |
D |
$95.21 |
$46,653 |
D/D |
(490) |
8,993 |
0 |
- |
|
| CELG |
Celgene Corp |
SEE REMARKS |
• – – |
2019-10-31 |
4 |
D |
$108.03 |
$121,318 |
D/D |
(1,123) |
4,313 |
0 |
- |
|
| CELG |
Celgene Corp |
PRES., GLBL INFLAM. AND IMMUN. |
• – – |
2019-11-20 |
4 |
D |
$0.00 |
$0 |
I/I |
(327) |
0 |
0 |
- |
|
| CELG |
Celgene Corp |
PRES., GLBL INFLAM. AND IMMUN. |
• – – |
2019-11-20 |
4 |
D |
$0.00 |
$0 |
D/D |
(37,181) |
0 |
0 |
- |
|
| MYOV |
Myovant Sciences Ltd. |
Director |
– • – |
2023-03-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(3,673) |
0 |
0 |
- |
|
42 Records found
|
|
Page 1 of 2 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
